- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
Opportunities for Emerging Disease-Modifying Therapies in Multiple Sclerosis
Summary
11 Jun 2008 — Webinar, 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris)
This presentation is based on our Treatment Algorithms in Multiple Sclerosis report. This report shows which disease-modifying biologic therapies gain the greatest patient shares in the earliest lines of therapy and the key factors driving therapy choice among physicians.
Contact details
email: mtulp@decisionresources.be phone: +32 2 357 06 10
Booking
| No fee |
Venue
Webinar
Webinar — 11 Jun Wed
10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
This presentation is based on our Treatment Algorithms in Multiple Sclerosis report. This report shows which disease-modifying biologic therapies gain the greatest patient shares in the earliest lines of therapy and the key factors driving therapy choice among physicians. The interferon-beta therapies make up the lion's share of the multiple sclerosis market, but Teva Pharmaceutical's Copaxone has been gaining significant market share because of its benign side-effect/safety profile.
NO FEE: This is a complimentary webinar, which is open to all.
Treatment Algorithms in Multiple Sclerosis combines in-depth primary research from 150 surveyed physicians with the most extensive claims-based longitudinal patient-level data from PharMetrics to provide insight on quantitative patient share by lines of therapy for multiple sclerosis.
Presented by Decision Resources Director Madhuri Borde, Ph.D., the webinar will answer the following questions:
· How many newly diagnosed patients with multiple sclerosis are not currently treated with an interferon-beta therapy or Copaxone? What key barriers prevent patients from receiving disease-modifying drug treatment? What opportunity does this present for agents seeking to capture patient share in early-stage disease?
· What factors lead physicians to prescribe one disease-modifying therapy over another? Based on these agents' positioning in first- and second-line treatment, which attributes have the greatest potential for maximizing patient share?
· According to surveyed physicians, at what point in the treatment algorithm are key emerging therapies-most notably Novartis/Mitsubishi Tanabe's fingolimod-likely to gain their most use? How will this impact the use of current multiple sclerosis therapies in lines of therapy?
Dr. Borde and Therapeutic Area Director Jason LaBonte, Ph.D., will conduct a live Q & A session after the presentation.
To register, click here to reach our WebEx Event Center page, then click "Register" for this event.
For more information, contact Christopher Comfort at ccomfort@dresources.com.
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us